Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Eikon Therapeutics, Inc. ( (EIKN) ) is now available.
Eikon Therapeutics reported its first quarter 2026 results on May 11, 2026, highlighting a cash position of $596 million and a net loss of $83 million as it ramps investment in its oncology pipeline. Research and development expenses rose 24% year on year to $70 million, driven by expanded clinical trial activity and a milestone payment tied to advancing its PARP1 inhibitor EIK1003 into Phase 2, while general and administrative costs increased 17% following the occupation of its Millbrae headquarters.
Operationally, the company emphasized progress across three priority oncology programs: TLR7/8 agonist EIK1001 in Phase 2/3 studies for melanoma and non-small cell lung cancer, selective PARP1 inhibitor EIK1003 in Phase 1/2 and Phase 2 dose optimization trials across multiple tumor types, and WRN helicase inhibitor EIK1005, which entered a Phase 1/2 trial for advanced solid tumors in February 2026. Eikon underscored growing clinical validation of its pipeline with six abstracts accepted for presentation at the 2026 ASCO annual meeting and a Journal of Medicinal Chemistry publication showcasing its single molecule tracking platform, signaling an intensifying push to build scientific credibility and support future development milestones.
The most recent analyst rating on (EIKN) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Eikon Therapeutics, Inc. stock, see the EIKN Stock Forecast page.
More about Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative oncology medicines to address serious unmet medical needs. The company leverages a proprietary single molecule tracking technology platform to discover and optimize internally derived drug candidates while also in-licensing promising assets, with a vision of becoming a fully integrated global leader in oncology therapeutics.
Average Trading Volume: 344,988
Learn more about EIKN stock on TipRanks’ Stock Analysis page.